Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilson H Miller

Showing results (101-110 of 168) with videos related to

Pageof 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2022
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 StudyDavid M O'Malley, Giovanni Mendonca Bariani, Philippe A Cassier, et al.
Nature Communications|December 8, 2020
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanomaAntoni Ribas, Alain Algazi, Paolo A Ascierto, et al.
Gynecologic Oncology|January 23, 2025
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study resultsDavid M O'Malley, Giovani M Bariani, Philippe A Cassier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancerFilippa Pettersson, Christina Yau, Monica C Dobocan, et al.
International Journal of Molecular Sciences|April 23, 2022
A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue SpecimensGeorgia Mitsa, Qianyu Guo, Christophe Goncalves, et al.
BMC Cancer|July 25, 2024
Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label studyByoung Chul Cho, Irene Braña, Beatriz Cirauqui, et al.
Journal of the American Academy of Dermatology|June 12, 2026
Immune Checkpoint Inhibitor-Associated Autoimmune Bullous Disease: A Clinical ReviewHouriah Y Nukaly, Ghassan Barnawi, Husna Irfan Thalib, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trialDanial Khan Hadi, Kelly J Baines, Behnam Jabbarizadeh, et al.
Cancers|June 2, 2021
Defining the Criteria for Reflex Testing for <i>BRAF</i> Mutations in Cutaneous Melanoma PatientsSarah Zhou, Daniel Sikorski, Honghao Xu, et al.
Molecular Cancer Therapeutics|January 28, 2022
Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like PhenotypeSamuel E J Preston, Audrey Emond, Filippa Pettersson, et al.
Pageof 17

Showing results (101-110 of 168) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2022
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 StudyDavid M O'Malley, Giovanni Mendonca Bariani, Philippe A Cassier, et al.
Nature Communications|December 8, 2020
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanomaAntoni Ribas, Alain Algazi, Paolo A Ascierto, et al.
Gynecologic Oncology|January 23, 2025
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study resultsDavid M O'Malley, Giovani M Bariani, Philippe A Cassier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancerFilippa Pettersson, Christina Yau, Monica C Dobocan, et al.
International Journal of Molecular Sciences|April 23, 2022
A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue SpecimensGeorgia Mitsa, Qianyu Guo, Christophe Goncalves, et al.
BMC Cancer|July 25, 2024
Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label studyByoung Chul Cho, Irene Braña, Beatriz Cirauqui, et al.
Journal of the American Academy of Dermatology|June 12, 2026
Immune Checkpoint Inhibitor-Associated Autoimmune Bullous Disease: A Clinical ReviewHouriah Y Nukaly, Ghassan Barnawi, Husna Irfan Thalib, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trialDanial Khan Hadi, Kelly J Baines, Behnam Jabbarizadeh, et al.
Cancers|June 2, 2021
Defining the Criteria for Reflex Testing for <i>BRAF</i> Mutations in Cutaneous Melanoma PatientsSarah Zhou, Daniel Sikorski, Honghao Xu, et al.
Molecular Cancer Therapeutics|January 28, 2022
Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like PhenotypeSamuel E J Preston, Audrey Emond, Filippa Pettersson, et al.
Pageof 17